HealthBio, Inc. is a late-stage clinical immunology company developing products for immune-mediated chronic diseases. The company's core discovery is that persistent activation of monocytes and macrophages, and the vascular inflammation that follows, is a central driver of these conditions. Its lead candidate, ImmunoRoc™, a patented combination therapy, drives immune reset through a novel method of targeting this pathway. ImmunoRoc is currently being evaluated in the Phase 2/3 IMPACT trial for Long COVID, with a pivotal readout expected in 1Q27. A Phase 2/3 protocol for Post-Treatment Lyme Disease Syndrome (PTLDS) has also been submitted to the FDA.

The company's IncellKINE™ platform is a blood-based multiplex cytokine assay that differentiates Long COVID, PTLDS, and ME/CFS (indications with no established diagnostic standard) and supports patient stratification in clinical trials.

Founded in 2009, HealthBio is headquartered in Traverse City, Michigan, with R&D and manufacturing in Hayward, California.